Edition:
United States

Fresenius SE & Co KGaA (FREG.DE)

FREG.DE on Xetra

64.98EUR
11:35am EDT
Change (% chg)

€0.72 (+1.12%)
Prev Close
€64.26
Open
€64.60
Day's High
€65.44
Day's Low
€64.38
Volume
878,294
Avg. Vol
1,310,144
52-wk High
€72.76
52-wk Low
€58.96

Select another date:

Tue, Jul 31 2018

Akorn row overshadows Fresenius' generics guidance

BERLIN Fears that a legal dispute with U.S. drugmaker Akorn could extend into next year overshadowed improved guidance from Germany's Fresenius SE for its Kabi generics business.

UPDATE 3-Akorn row overshadows Fresenius' generics guidance

* CEO says expect case to be resolved by early 2019 (Adds CEO comments from analyst call)

Fresenius nudges up Kabi earnings guidance

BERLIN, July 31 Fresenius SE nudged up its earnings guidance for its Kabi generics unit on Tuesday as it posted a 3 percent rise in adjusted group net profit in the second quarter.

Fresenius transfers inpatient rehabilitation business to Vamed unit

FRANKFURT, June 6 German healthcare group Fresenius said it was transferring its inpatient rehabilitation business from its private hospital operations to its Fresenius Vamed unit to better enable continued growth at the two businesses.

Fresenius CEO defends canceled Akorn deal

FRANKFURT/BERLIN Fresenius SE's chief executive has defended the company's decision to pull out of a planned $4.8 billion takeover of Akorn , saying it was the only option after uncovering data integrity breaches at the U.S drugmaker.

UPDATE 1-Fresenius CEO defends cancelled Akorn deal

* Expects legal proceedings to conclude in 2019 (Adds details on expenses, comment on provision, analyst)

BRIEF-Fresenius Costs Related To Akorn Total 60 Mln Euros So Far - CEO

* CEO SAYS COSTS RELATED TO AKORN TRANSACTION TOTAL 60 MILLION EUROS SO FAR

Fresenius CEO defends cancelled Akorn deal

FRANKFURT/BERLIN, May 18 Fresenius SE's chief executive has defended the company's decision to pull out of a planned $4.8 billion takeover of Akorn, saying it was the only option after uncovering data integrity breaches at the U.S drugmaker.

Fresenius sees Akorn lawsuit dragging on into 2019

BERLIN German healthcare group Fresenius SE said on Thursday its legal battle with Akorn over its canceled $4.7 billion takeover could drag on into 2019 as it posted a slight decline in quarterly profit hurt by a strong euro.

Fresenius Q1 net income slips 2 pct on strong euro

BERLIN, May 3 German healthcare group Fresenius SE posted a slight decline in quarterly profit on Thursday, hurt by a strong euro, and confirmed its full-year guidance.

Select another date: